Study of XmAb942 for active ulcerative colitis
Part of Digestive system clinical trials.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your ulcerative colitis must be moderately to severely active and diagnosed at least 3 months ago.
- At least one standard treatment for UC (like a biologic, Janus kinase inhibitor, or steroid) must have failed, stopped working, or caused side effects for you.
- You should not have other types of inflammatory bowel disease (like Crohn's disease) or certain other colon conditions.
- You must be able to have a colonoscopy showing the inflammation extends at least 6 inches from the anus.
- You should not have active infections (including C. difficile, hepatitis B/C, HIV), or heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This study tests an investigational pill for people with moderate-to-severe ulcerative colitis that has not improved with standard treatments. The goal is to see if the pill can reduce symptoms like bloody stools and frequent bowel movements.
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.